Evidence map›Paper›PMID 27892949›Full record

Trial reportBone marrow transplantation2017

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

T Ruutu, A Gratwohl, D Niederwieser, T de Witte, S van der Werf, A van Biezen, M Mohty, N Kröger, A Rambaldi, E McGrath and 4 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04397367 (Low Dose Ruxolitinib in Combination With Methylprednisolone 1mg/kg as Initial Therapy for Acute Graft-Versus-Host Disease), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04397367 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

Low Dose Ruxolitinib in Combination With Methylprednisolone 1mg/kg as Initial Therapy for Acute Graft-Versus-Host Disease

TypeinterventionalSponsorChinese PLA General HospitalRan2019 to 2020Enrolled38ConditionsaGVHD, Stem Cell Transplant ComplicationsArmsRuxolitinib 10 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg once a day combined with Corticosteroids, Ruxolitinib 2.5 mg once a day combined with Corticosteroids
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Long-Term Follow-Up ofBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

T RuutuComprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki University Hospital, Helsinki, Finland.
A GratwohlHematology, Medical Faculty, University of Basel, Basel, Switzerland.
D NiederwieserDepartment of Hematology/Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany.
T de WitteDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
S van der WerfEBMT Data Office Leiden, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
A van BiezenEBMT Data Office Leiden, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
M MohtyHopital Saint-Antoine, Paris, France.
N KrögerDepartment of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany.
A RambaldiHematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy.ORCID http://orcid.org/0000-0002-3739-7502
E McGrathEBMT Executive Office & JACIE Office, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1956-037X
A SuredaHaematology Department, Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain.
G BasakDepartment of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
H GreinixDivision of Haematology, Medical University of Graz, Graz, Austria.
R F DuarteHospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2013, recommendations for a standardized practice in the prophylaxis and treatment of GvHD were adopted and published by the European Society for Blood and Marrow Transplantation and the European LeukemiaNet. One year later, all 341 European Society for Blood and Marrow Transplantation centres performing allogeneic haematopoietic stem cell transplantation were contacted for a change-control analysis and asked to fill in a questionnaire; 111 centres (33%) responded. Of these, 83% had been aware of the recommendations. Paediatric centres (P=0.004), centres with shorter programme duration (P=0.049), not JACIE (the Joint Accreditation Committee of the International Society for Cellular Therapy and the European Society for Blood and Marrow Transplantation)-accredited centres (P=0.010) and centres from middle-income countries (P=0.033) were more likely to be unaware of the recommendations. Thirty-eight per cent of the centres regarded the recommendations as relevant guidelines affecting their policies, 61% as interesting information. Thirty per cent had decided to make changes in their institutional protocols based on the recommendations. More than 80% were willing to use the recommendations for a control arm in randomized studies. This survey shows that the published recommendations had some, though insufficient, impact on the strategies and methods of allogeneic haematopoietic stem cell transplantation applied by the centres. It also identified some of the weaknesses to be addressed when releasing recommendations in the future.

Indexed as

Guideline AdherenceHematopoietic Stem Cell TransplantationAdolescentAdultAllograftsChildChild, PreschoolFemaleFollow-Up StudiesGraft vs Host DiseaseHumansInfantMaleMiddle AgedPractice Guidelines as Topic

Identifiers

PMID27892949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.